The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 263-page report you will receive 116 charts– all unavailable elsewhere.
The 263-page report provides clear detailed insight into the leading 50 gastrointestinal therapeutic companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Our study discusses the selected leading companies that are the major players in the gastrointestinal drugs market: • Abbott • AbbVie • Alexion Pharmaceuticals • Allergan • ANI Pharmaceuticals, Inc. • AstraZeneca • Bayer AG • Biogen • Eisai Co., Ltd. • Eli Lilly • Evoke Pharma • GlaxoSmithKline • Intercept Pharmaceuticals • Ironwood Pharmaceuticals • Janssen Pharmaceutica • Kyowa Hakko Kirin Co. Ltd. • Mallinckrodt plc • Pfizer • Synergy Pharmaceuticals Inc. • Takeda • Cadila Healthcare Ltd. • Novartis AG • Shire • Merck & Co., Inc. • Lexicon Pharmaceuticals, Inc. • Sanofi • ETX Pharma, Inc. • Theravance Biopharma, Inc. • Other companies
• This report also discusses factors that drive and restrain the market, as well as opportunities in the gastrointestinal therapeutic market.
Visiongain’s study is intended for anyone requiring commercial analyses for the leading 50 gastrointestinal therapeutic companies. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com
1. Report Overview
1.1 Global Gastrointestinal Therapeutics Market Overview
1.2 Market Definition & Scope
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report?
1.6 Key Questions Answered by This Analytical Report
1.7 How This Report Delivers
1.8 Who is This Report For?
1.9 Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Gastrointestinal Therapeutics Market
2.1 Gastrointestinal Disorders
2.1.1 Functional gastrointestinal disorders
2.1.1.1 Constipation
2.1.1.2 Irritable Bowel Syndrome (IBS)
2.1.2 Structural gastrointestinal disorders
2.1.2.1 Haemorrhoids
2.1.2.2 Anal fissures
2.1.2.3 Perianal abscesses
2.1.2.4 Anal fistula
2.1.2.5 Diverticular disease
2.1.2.6 Colon polyps and cancer
2.1.3 Colitis
2.2 FDA Approved Drugs for Gastroenterology (2000-2018)
2.2.1 Drugs Approved in 2018
2.2.2 Drugs Approved in 2017
2.2.3 Drugs Approved in 2016
2.2.4 Drugs Approved in 2015
2.2.5 Drugs Approved in 2014
2.2.6 Drugs Approved in 2013
2.2.7 Drugs Approved in 2012
2.2.8 Drugs Approved in 2011
2.2.9 Drugs Approved in 2010
2.2.10 Drugs Approved in 2009
2.2.11 Drugs Approved in 2008
2.2.12 Drugs Approved in 2006
2.2.13 Drugs Approved in 2005
2.2.14 Drugs Approved in 2004
2.2.15 Drugs Approved in 2003
2.2.16 Drugs Approved in 2002
2.2.17 Drugs Approved in 2001
2.2.18 Drugs Approved in 2000
2.3 Market Dynamics
2.3.1 Drivers
2.3.1.1 Rising Disease Prevalence
2.3.1.2 Increase in the Number of Aging Population
2.3.1.3 Increased Demand in Market
2.3.2 Restraints
2.3.2.1 Lengthy & stringent government regulations
2.3.2.2 Competition from Generic Drugs
2.3.3 Opportunities
2.3.3.1 Increase in purchasing power of emerging economies
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
